tiprankstipranks
Insmed: Data from Phase 3 ASPEN study of Brensocatib due in latter part of 2Q
The Fly

Insmed: Data from Phase 3 ASPEN study of Brensocatib due in latter part of 2Q

Enrollment in the Phase 2 study of TPIP in patients with PH-ILD completed in November 2023; Topline data expected in 2Q 2024.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on INSM:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles